2026 EU MDR Deadlines: What Device Manufacturers Need to Know

Three EU MDR enforcement windows land in 2026. Two of them arrive this month. If your regulatory team is still running on spreadsheets and manual tracking, the clock has already started.

This article covers each deadline — what it actually requires, who it affects, and the concrete preparation steps that move the needle before enforcement kicks in. We're not going to pad this with regulatory background you already know. You're here because you need to act.

The Three Deadlines

What May 26 Actually Means for Class III Implant Manufacturers

Custom-made implants have historically operated under Article 52(8) MDR, which provided a lighter-touch conformity assessment path. That path closes on May 26.

Who this hits hardest: Orthopedic implant manufacturers producing patient-specific devices, dental implant labs with patient-matched components, and cardiovascular device makers using patient-specific design parameters. If your manufacturing process produces devices tailored to individual patient anatomy or measurements, this is your deadline.

What full MDR compliance requires at this stage:

• A complete technical documentation file meeting Annex II and III of MDR
• A clinical evaluation report (CER) — not just a literature review, a structured evaluation against MEDDEV 2.7/1 rev 4 criteria
• Post-market surveillance plan and initial PSUR or periodic safety update
• Written statement to the patient and treating clinician (for custom devices not requiring notified body involvement)
• For implantable Class III custom devices requiring notified body involvement: conformity assessment complete, CE mark in place

If your notified body assessment isn't already complete or well underway, May 26 is not achievable for devices requiring NB involvement. The realistic path now is to document your compliance gap, prepare a remediation timeline, and keep existing compliant devices in distribution while you complete assessment for the non-compliant portfolio.

What May 28 Means for EUDAMED Registration

EUDAMED has been operational in voluntary mode since May 2022. Phase 1 mandatory enforcement covers the actor and device registration modules. The scope is broader than most teams realize on first pass.

Actor Registration (mandatory from May 28)

Every manufacturer, EU authorized representative, importer, and distributor placing MDR-regulated devices on the EU market must have a completed EUDAMED actor registration. This is the prerequisite — you can't register devices without it. If you haven't done this, it's your first action item.

Device Registration / UDI (mandatory from May 28)

Device registration in EUDAMED is now mandatory for devices covered by MDR 2017/745 and IVDR 2017/746. This requires:

• UDI-DI assignment for each device model (via an accredited issuing entity — GS1, HIBCC, or ICCBBA)
• Basic UDI-DI registered in EUDAMED with required device data fields populated
• Device registration record linked to the manufacturer actor registration
• Certificate information linked (for certified devices)

The practical bottleneck: UDI assignment takes time if you're starting from scratch. Issuing entities have onboarding queues. If you haven't started, begin today — waiting until May 27 is not a plan.

What's NOT in Phase 1

The notified body and certificate modules, the clinical investigation module, and the vigilance module are not yet mandatory in Phase 1. The Commission will announce the Phase 2-4 dates separately. Don't let Phase 2 scope distract from getting Phase 1 done.

What November 28 Means for Legacy MDD Devices

Devices currently on the EU market under MDD (Medical Devices Directive) or AIMDD (Active Implantable Medical Devices Directive) certificates — which received transition period extensions under Article 120 MDR — face a registration requirement deadline on November 28.

This applies to devices that are:

• Lawfully placed on the EU market under MDD/AIMDD before MDR transition
• Covered by valid MDD/AIMDD certificates from a notified body (with transition period extensions granted by Commission Regulation 2023/607)
• Continuing to be sold or distributed in the EU without a full MDR conformity assessment

The November 28 deadline doesn't require MDR conformity — it requires EUDAMED registration of these legacy devices while they remain in distribution under their MDD/AIMDD certificates. Think of it as the EU's visibility requirement: they want to know what's on the market, even under the old framework.

Action: Compile your legacy device inventory, map each device to its MDD/AIMDD certificate status, and schedule EUDAMED registrations. Six months is enough time if you start now. It's not enough time if you wait until October.

Preparation Checklist

A Note on AI Tools and Regulatory Readiness

The preparation steps above are straightforward on paper. The execution bottleneck is almost always documentation velocity — technical files, clinical evaluations, and UDI data entry take more calendar time than regulatory teams expect, especially when the underlying documentation was built for MDD, not MDR.

AI-assisted regulatory tools — including PrediClear — are starting to close that gap. Not by replacing the qualified professional's judgment, but by accelerating the research, gap analysis, and documentation assembly that currently runs on spreadsheets and tribal knowledge. A CER that takes 6 weeks to compile manually can be scaffolded in a fraction of the time when predicate research, clinical literature search, and equivalence assessment are AI-assisted.

That's the value proposition for teams facing a May 26 or May 28 deadline they're not ready for: compress the time from "we know what's required" to "we have documentation that demonstrates it."